The classical AT(N) biomarker paradigm defines AD based on the development of amyloid-β (Aβ) plaques, neurofibrillary tau tangles, and structural atrophy in brain regions critical for memory and cognition (6). The gene discussed is MAPT; the disease is Alzheimer disease.